News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Vertex Pharmaceuticals (MA) (VRTX) Soars as Cystic Fibrosis Drug Regimen Improves Patients’ Breathing



5/7/2012 8:00:56 AM

Vertex Pharmaceuticals Inc. (VRTX), maker of the first medicine to target the underlying cause of cystic fibrosis, gained the most ever after a combination of that drug and a second therapy improved patients’ breathing ability. Vertex climbed 41 percent to $52.57 at 9:32 a.m. New York time, after touching $53.94 for the biggest intraday increase since the company’s shares began trading publicly in 1991. The combination of Kalydeco, approved in January, and the experimental VX-809 improved lung function by at least five percentage points in 46 percent of patients in a mid-stage study, the Cambridge, Massachusetts-based company said today in a statement.

Read at Bloomberg
Read at Forbes
Read at Reuters
Read at Wall Street Journal


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES